Masatoshi Kudo

Masatoshi Kudo is a leading Japanese hepatologist and liver cancer specialist who has contributed extensively to HCC treatment including locoregional therapy and systemic treatment. He was the principal investigator of the REFLECT trial comparing lenvatinib to sorafenib as first-line therapy for advanced HCC, establishing lenvatinib as an alternative standard option. He has contributed to TACE optimization and HCC imaging research. He edits Liver Cancer journal and has been a key voice in adapting global HCC treatment approaches for Asian patient populations with predominantly HBV-related disease.